Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial

NCT01119963 is registered in ClinicalTrials.gov with Obstetrix Medical Group as lead sponsor.

NCT NCT01119963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01119963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Lead sponsor
Obstetrix Medical Group
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2011
Completion date
October 31, 2014
Enrollment
152 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

preterm delivery